We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.
ITCI

Delisted

ITCI was delisted on the 1st of April, 2025.

Back to rankings

274 hedge funds and large institutions have $3.85B invested in Intra-Cellular Therapies Inc. in 2022 Q3 according to their latest regulatory filings, with 43 funds opening new positions, 103 increasing their positions, 86 reducing their positions, and 35 closing their positions.

New
Increased
Maintained
Reduced
Closed

23% more first-time investments, than exits

New positions opened: 43 | Existing positions closed: 35

20% more repeat investments, than reductions

Existing positions increased: 103 | Existing positions reduced: 86

13% more call options, than puts

Call options by funds: $21.3M | Put options by funds: $18.9M

3% more funds holding

Funds holding: 266 → 274 (+8)

16% less capital invested

Capital invested by funds: $4.57B → $3.85B (-$727M)

36% less funds holding in top 10

Funds holding in top 10: 11 → 7 (-4)

Holders
274
Holders Change
+8
Holders Change %
+3.01%
% of All Funds
4.72%
Holding in Top 10
7
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-36.36%
% of All Funds
0.12%
New
43
Increased
103
Reduced
86
Closed
35
Calls
$21.3M
Puts
$18.9M
Net Calls
+$2.43M
Net Calls Change
-$6.17M

Top Buyers

1
GKIM
GW&K Investment Management
Massachusetts
+$46.1M
2
Invesco
Invesco
Georgia
+$45.3M
3
Millennium Management
Millennium Management
New York
+$42M
4
Wellington Management Group
Wellington Management Group
Massachusetts
+$36.3M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
+$34.3M

Top Sellers

1
Victory Capital Management
Victory Capital Management
Texas
-$43.9M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$36.5M
3
DCM
Driehaus Capital Management
Illinois
-$29.4M
4
SCM
Suvretta Capital Management
New York
-$25.4M
5
CAM
Cormorant Asset Management
Massachusetts
-$15.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
M&T Bank
201
M&T Bank
New York
$274K +$115K +2,196 +59%
X
202
Xponance
Pennsylvania
$260K +$34.8K +666 +13%
MLICM
203
Metropolitan Life Insurance Company (MetLife)
New York
$257K – – –
Balyasny Asset Management
204
Balyasny Asset Management
Illinois
$247K +$277K +5,308 New
CC
205
Cipher Capital
New York
$247K +$277K +5,308 New
SG
206
Stonnington Group
California
$244K -$78.4K -1,500 -22%
PAS
207
Park Avenue Securities
New York
$237K +$266K +5,098 New
ACM
208
AlphaCrest Capital Management
New York
$232K -$274K -5,253 -51%
Rafferty Asset Management
209
Rafferty Asset Management
New York
$220K +$13.1K +251 +6%
UB
210
UMB Bank
Missouri
$217K – – –
AWCI
211
Alpine Woods Capital Investors
New York
$209K -$10.4K -200 -4%
RJT
212
Raymond James Trust
Florida
$208K +$5.54K +106 +2%
II
213
Inspire Investing
Idaho
$207K +$232K +4,447 New
Nisa Investment Advisors
214
Nisa Investment Advisors
Missouri
$205K +$19.4K +371 +9%
VEA
215
Virtus ETF Advisers
New York
$203K +$3.19K +61 +1%
Canada Life
216
Canada Life
Manitoba, Canada
$199K – – –
Russell Investments Group
217
Russell Investments Group
United Kingdom
$176K -$5.49M -105,073 -97%
CJL
218
Cyrus J. Lawrence
New York
$165K – – –
Rockefeller Capital Management
219
Rockefeller Capital Management
New York
$162K +$171K +3,274 +1,502%
Osaic Holdings
220
Osaic Holdings
Arizona
$154K -$712K -13,624 -80%
UBS Group
221
UBS Group
Switzerland
$121K -$49.3K -943 -27%
PA
222
Parallel Advisors
California
$117K +$157 +3 +0.1%
ETC
223
Exchange Traded Concepts
Oklahoma
$109K +$54.8K +1,049 +81%
C
224
Covestor
United Kingdom
$88K +$88.8K +1,699 +899%
Group One Trading
225
Group One Trading
Illinois
$67K +$75.7K +1,450 New
7 8
9
10 11

ITCI Hedge Fund Activity: Q3 2022 in Review

274 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q3 2022, worth a combined $3.85B — down 16% from $4.57B a quarter earlier.

Buyers outnumbered sellers: 43 funds opened new ITCI positions and 35 closed out — a net gain of 8 holders — while 103 added to existing stakes and 86 trimmed.

The largest buyer was GW&K Investment Management, adding an estimated $46.1M. The largest seller was Victory Capital Management, cutting an estimated $43.9M.

  • 274 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q3 2022, up from 266 in Q2 2022.
  • Funds reported $3.85B of Intra-Cellular Therapies Inc. stock for Q3 2022, down 16% quarter-over-quarter.
  • 43 funds opened new Intra-Cellular Therapies Inc. positions in Q3 2022 and 35 closed out, a net change of +8 holders.
  • The largest Intra-Cellular Therapies Inc. buyer in Q3 2022 was GW&K Investment Management, an estimated $46.1M added.
  • The largest Intra-Cellular Therapies Inc. seller in Q3 2022 was Victory Capital Management, an estimated $43.9M sold.

Based on aggregated 13F filings for Q3 2022.